Table 3.

Example 2 Results. Predicted sojourn times and mortality for patients in data example from Grein et al. [9] at 28 days of follow-up. Start: time of treatment initiation, Non-MV: noninvasive positive pressure ventilation, nasal high-flow oxygen therapy, low-flow oxygen, and ambient air, MV: ECMO and MV (): 95% confidence interval for duration estimates, (): standard error for risk estimates

	53 patients with severe COVID-19 treated with Remdesivir (Grein et al.), results at day 28
	Non-MV Duration in Days	MV Duration in Days	Total Length of ICU Stay in Days	Death Risk
Start Non-MV	16.26 (13.87, 18.56)	1.41 (0.27, 2.96)	17.67 (14.14, 21.52)	6.2% (3.3)
Start MV	6.14 (3.86, 8.41)	14.57 (11.99, 17.31)	20.71 (15.85, 25.72)	19.8% (6.4)
Full Cohort	9.77 (7.76, 11.81)	9.85 (7.68, 12.14)	19.62 (15.44, 23.95)	15.0% (5.3)